Wu, S.; Edwards, H.; Wang, D.; Liu, S.; Qiao, X.; Carter, J.; Wang, Y.; Taub, J.W.; Wang, G.; Ge, Y.
Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Cells 2022, 11, 2752.
https://doi.org/10.3390/cells11172752
AMA Style
Wu S, Edwards H, Wang D, Liu S, Qiao X, Carter J, Wang Y, Taub JW, Wang G, Ge Y.
Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Cells. 2022; 11(17):2752.
https://doi.org/10.3390/cells11172752
Chicago/Turabian Style
Wu, Shuangshuang, Holly Edwards, Deying Wang, Shuang Liu, Xinan Qiao, Jenna Carter, Yue Wang, Jeffrey W. Taub, Guan Wang, and Yubin Ge.
2022. "Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia" Cells 11, no. 17: 2752.
https://doi.org/10.3390/cells11172752
APA Style
Wu, S., Edwards, H., Wang, D., Liu, S., Qiao, X., Carter, J., Wang, Y., Taub, J. W., Wang, G., & Ge, Y.
(2022). Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia. Cells, 11(17), 2752.
https://doi.org/10.3390/cells11172752